Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Neisseria meningitidis Infections Drug market report explains the definition, types, applications, major countries, and major players of the Neisseria meningitidis Infections Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Griffith University
GlaxoSmithKline Plc
Wellstat Vaccines LLC
MGB Biopharma Ltd
Pfizer Inc
Beijing Minhai Biotechnology Co Ltd
Serum Institute of India Ltd
Panacea Biotec Ltd
Sanofi Pasteur SA
ImmunoBiology Ltd
JN-International Medical Corp
Biological E Ltd
China National Pharmaceutical Group Corp
By Type:
MGBBP-3
NCL-195
TP-10
Others
By End-User:
Hospital
Clinic
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Neisseria meningitidis Infections Drug Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Neisseria meningitidis Infections Drug Outlook to 2028- Original Forecasts
-
2.2 Neisseria meningitidis Infections Drug Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Neisseria meningitidis Infections Drug Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Neisseria meningitidis Infections Drug Market- Recent Developments
-
6.1 Neisseria meningitidis Infections Drug Market News and Developments
-
6.2 Neisseria meningitidis Infections Drug Market Deals Landscape
7 Neisseria meningitidis Infections Drug Raw Materials and Cost Structure Analysis
-
7.1 Neisseria meningitidis Infections Drug Key Raw Materials
-
7.2 Neisseria meningitidis Infections Drug Price Trend of Key Raw Materials
-
7.3 Neisseria meningitidis Infections Drug Key Suppliers of Raw Materials
-
7.4 Neisseria meningitidis Infections Drug Market Concentration Rate of Raw Materials
-
7.5 Neisseria meningitidis Infections Drug Cost Structure Analysis
-
7.5.1 Neisseria meningitidis Infections Drug Raw Materials Analysis
-
7.5.2 Neisseria meningitidis Infections Drug Labor Cost Analysis
-
7.5.3 Neisseria meningitidis Infections Drug Manufacturing Expenses Analysis
8 Global Neisseria meningitidis Infections Drug Import and Export Analysis (Top 10 Countries)
-
8.1 Global Neisseria meningitidis Infections Drug Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Neisseria meningitidis Infections Drug Export by Region (Top 10 Countries) (2017-2028)
9 Global Neisseria meningitidis Infections Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Neisseria meningitidis Infections Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global MGBBP-3 Consumption and Growth Rate (2017-2022)
-
9.1.2 Global NCL-195 Consumption and Growth Rate (2017-2022)
-
9.1.3 Global TP-10 Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Neisseria meningitidis Infections Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Neisseria meningitidis Infections Drug Market Analysis and Outlook till 2022
-
10.1 Global Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.2.2 Canada Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.2.3 Mexico Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3.2 UK Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3.3 Spain Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3.4 Belgium Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3.5 France Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3.6 Italy Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3.7 Denmark Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3.8 Finland Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3.9 Norway Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3.10 Sweden Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3.11 Poland Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3.12 Russia Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.3.13 Turkey Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.4.2 Japan Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.4.3 India Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.4.4 South Korea Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.4.5 Pakistan Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.4.6 Bangladesh Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.4.7 Indonesia Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.4.8 Thailand Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.4.9 Singapore Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.4.10 Malaysia Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.4.11 Philippines Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.4.12 Vietnam Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.5.2 Colombia Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.5.3 Chile Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.5.4 Argentina Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.5.5 Venezuela Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.5.6 Peru Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.5.7 Puerto Rico Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.5.8 Ecuador Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.6.2 Kuwait Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.6.3 Oman Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.6.4 Qatar Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.6.5 Saudi Arabia Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.6.6 United Arab Emirates Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.7.2 South Africa Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.7.3 Egypt Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.7.4 Algeria Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Neisseria meningitidis Infections Drug Consumption (2017-2022)
-
10.8.2 New Zealand Neisseria meningitidis Infections Drug Consumption (2017-2022)
11 Global Neisseria meningitidis Infections Drug Competitive Analysis
-
11.1 Griffith University
-
11.1.1 Griffith University Company Details
-
11.1.2 Griffith University Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Griffith University Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.1.4 Griffith University Neisseria meningitidis Infections Drug Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 GlaxoSmithKline Plc
-
11.2.1 GlaxoSmithKline Plc Company Details
-
11.2.2 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.2.4 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Wellstat Vaccines LLC
-
11.3.1 Wellstat Vaccines LLC Company Details
-
11.3.2 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.3.4 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 MGB Biopharma Ltd
-
11.4.1 MGB Biopharma Ltd Company Details
-
11.4.2 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.4.4 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Pfizer Inc
-
11.5.1 Pfizer Inc Company Details
-
11.5.2 Pfizer Inc Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Pfizer Inc Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.5.4 Pfizer Inc Neisseria meningitidis Infections Drug Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Beijing Minhai Biotechnology Co Ltd
-
11.6.1 Beijing Minhai Biotechnology Co Ltd Company Details
-
11.6.2 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.6.4 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Serum Institute of India Ltd
-
11.7.1 Serum Institute of India Ltd Company Details
-
11.7.2 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.7.4 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Panacea Biotec Ltd
-
11.8.1 Panacea Biotec Ltd Company Details
-
11.8.2 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.8.4 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Sanofi Pasteur SA
-
11.9.1 Sanofi Pasteur SA Company Details
-
11.9.2 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.9.4 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 ImmunoBiology Ltd
-
11.10.1 ImmunoBiology Ltd Company Details
-
11.10.2 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.10.4 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 JN-International Medical Corp
-
11.11.1 JN-International Medical Corp Company Details
-
11.11.2 JN-International Medical Corp Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 JN-International Medical Corp Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.11.4 JN-International Medical Corp Neisseria meningitidis Infections Drug Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Biological E Ltd
-
11.12.1 Biological E Ltd Company Details
-
11.12.2 Biological E Ltd Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Biological E Ltd Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.12.4 Biological E Ltd Neisseria meningitidis Infections Drug Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 China National Pharmaceutical Group Corp
-
11.13.1 China National Pharmaceutical Group Corp Company Details
-
11.13.2 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Main Business and Markets Served
-
11.13.4 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Product Portfolio
-
11.13.5 Recent Research and Development Strategies
12 Global Neisseria meningitidis Infections Drug Market Outlook by Types and Applications to 2028
-
12.1 Global Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global MGBBP-3 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global NCL-195 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global TP-10 Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Neisseria meningitidis Infections Drug Market Analysis and Outlook to 2028
-
13.1 Global Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.2.2 Canada Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.2.3 Mexico Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3.2 UK Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3.3 Spain Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3.4 Belgium Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3.5 France Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3.6 Italy Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3.7 Denmark Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3.8 Finland Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3.9 Norway Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3.10 Sweden Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3.11 Poland Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3.12 Russia Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.3.13 Turkey Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.4.2 Japan Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.4.3 India Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.4.4 South Korea Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.4.8 Thailand Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.4.9 Singapore Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.4.11 Philippines Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.5.2 Colombia Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.5.3 Chile Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.5.4 Argentina Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.5.6 Peru Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.6.3 Oman Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.6.4 Qatar Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.7.2 South Africa Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.7.3 Egypt Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.7.4 Algeria Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Neisseria meningitidis Infections Drug Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Neisseria meningitidis Infections Drug
-
Figure of Neisseria meningitidis Infections Drug Picture
-
Table Global Neisseria meningitidis Infections Drug Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Neisseria meningitidis Infections Drug Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global MGBBP-3 Consumption and Growth Rate (2017-2022)
-
Figure Global NCL-195 Consumption and Growth Rate (2017-2022)
-
Figure Global TP-10 Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Neisseria meningitidis Infections Drug Consumption by Country (2017-2022)
-
Table North America Neisseria meningitidis Infections Drug Consumption by Country (2017-2022)
-
Figure United States Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Canada Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Mexico Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Neisseria meningitidis Infections Drug Consumption by Country (2017-2022)
-
Figure Germany Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure UK Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Spain Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Belgium Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure France Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Italy Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Denmark Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Finland Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Norway Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Sweden Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Poland Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Russia Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Turkey Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Table APAC Neisseria meningitidis Infections Drug Consumption by Country (2017-2022)
-
Figure China Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure India Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Thailand Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Singapore Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Philippines Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Table South America Neisseria meningitidis Infections Drug Consumption by Country (2017-2022)
-
Figure Brazil Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Colombia Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Chile Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Argentina Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Peru Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Table GCC Neisseria meningitidis Infections Drug Consumption by Country (2017-2022)
-
Figure Bahrain Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Oman Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Qatar Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Table Africa Neisseria meningitidis Infections Drug Consumption by Country (2017-2022)
-
Figure Nigeria Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure South Africa Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Egypt Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure Algeria Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Table Oceania Neisseria meningitidis Infections Drug Consumption by Country (2017-2022)
-
Figure Australia Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Neisseria meningitidis Infections Drug Consumption and Growth Rate (2017-2022)
-
Table Griffith University Company Details
-
Table Griffith University Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Griffith University Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table Griffith University Neisseria meningitidis Infections Drug Product Portfolio
-
Table GlaxoSmithKline Plc Company Details
-
Table GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Product Portfolio
-
Table Wellstat Vaccines LLC Company Details
-
Table Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Product Portfolio
-
Table MGB Biopharma Ltd Company Details
-
Table MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table MGB Biopharma Ltd Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table MGB Biopharma Ltd Neisseria meningitidis Infections Drug Product Portfolio
-
Table Pfizer Inc Company Details
-
Table Pfizer Inc Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Inc Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table Pfizer Inc Neisseria meningitidis Infections Drug Product Portfolio
-
Table Beijing Minhai Biotechnology Co Ltd Company Details
-
Table Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Product Portfolio
-
Table Serum Institute of India Ltd Company Details
-
Table Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Serum Institute of India Ltd Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table Serum Institute of India Ltd Neisseria meningitidis Infections Drug Product Portfolio
-
Table Panacea Biotec Ltd Company Details
-
Table Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Panacea Biotec Ltd Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table Panacea Biotec Ltd Neisseria meningitidis Infections Drug Product Portfolio
-
Table Sanofi Pasteur SA Company Details
-
Table Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Pasteur SA Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table Sanofi Pasteur SA Neisseria meningitidis Infections Drug Product Portfolio
-
Table ImmunoBiology Ltd Company Details
-
Table ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table ImmunoBiology Ltd Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table ImmunoBiology Ltd Neisseria meningitidis Infections Drug Product Portfolio
-
Table JN-International Medical Corp Company Details
-
Table JN-International Medical Corp Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table JN-International Medical Corp Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table JN-International Medical Corp Neisseria meningitidis Infections Drug Product Portfolio
-
Table Biological E Ltd Company Details
-
Table Biological E Ltd Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biological E Ltd Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table Biological E Ltd Neisseria meningitidis Infections Drug Product Portfolio
-
Table China National Pharmaceutical Group Corp Company Details
-
Table China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Main Business and Markets Served
-
Table China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Product Portfolio
-
Figure Global MGBBP-3 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global NCL-195 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global TP-10 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Neisseria meningitidis Infections Drug Consumption Forecast by Country (2022-2028)
-
Table North America Neisseria meningitidis Infections Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Neisseria meningitidis Infections Drug Consumption Forecast by Country (2022-2028)
-
Figure Germany Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Neisseria meningitidis Infections Drug Consumption Forecast by Country (2022-2028)
-
Figure China Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Neisseria meningitidis Infections Drug Consumption Forecast by Country (2022-2028)
-
Figure Brazil Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Neisseria meningitidis Infections Drug Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Neisseria meningitidis Infections Drug Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Neisseria meningitidis Infections Drug Consumption Forecast by Country (2022-2028)
-
Figure Australia Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Neisseria meningitidis Infections Drug Consumption Forecast and Growth Rate (2022-2028)
-
